国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2009年
13期
792-795
,共4页
支气管哮喘%IL-13%IL-13受体
支氣管哮喘%IL-13%IL-13受體
지기관효천%IL-13%IL-13수체
Bronchial asthma%Interleukin-13%IL-13 receptor
支气管哮喘(简称哮喘)是最常见的过敏性疾病,它是多种细胞参与的慢性气道炎症.大量的实验研究已证实,白介素13(interleukin-13,IL-13)在哮喘发病机制中起中轴作用.也有研究表明,编码IL-13的信号分子的几个基因的遗传联合在哮喘患者体内有很高的表达.因此,众多哮喘的治疗因子中,IL-13及其信号途径作为有前景的治疗靶位点终将展示其诱人的临床价值,为哮喘治疗提供新思路.那么应用IL-13的对抗物阻断IL-13的生物活性对于改善治疗哮喘应该是一个好策略.
支氣管哮喘(簡稱哮喘)是最常見的過敏性疾病,它是多種細胞參與的慢性氣道炎癥.大量的實驗研究已證實,白介素13(interleukin-13,IL-13)在哮喘髮病機製中起中軸作用.也有研究錶明,編碼IL-13的信號分子的幾箇基因的遺傳聯閤在哮喘患者體內有很高的錶達.因此,衆多哮喘的治療因子中,IL-13及其信號途徑作為有前景的治療靶位點終將展示其誘人的臨床價值,為哮喘治療提供新思路.那麽應用IL-13的對抗物阻斷IL-13的生物活性對于改善治療哮喘應該是一箇好策略.
지기관효천(간칭효천)시최상견적과민성질병,타시다충세포삼여적만성기도염증.대량적실험연구이증실,백개소13(interleukin-13,IL-13)재효천발병궤제중기중축작용.야유연구표명,편마IL-13적신호분자적궤개기인적유전연합재효천환자체내유흔고적표체.인차,음다효천적치료인자중,IL-13급기신호도경작위유전경적치료파위점종장전시기유인적림상개치,위효천치료제공신사로.나요응용IL-13적대항물조단IL-13적생물활성대우개선치료효천응해시일개호책략.
The incidence of allergic diseases has dramatically increased in recent decades, especially in urban and industrialized areas. It is important socially as well as medically to establish more useful strategies to overcome allergic disorders. Bronchial asthma (asthma) is a complex disease characterized by airway inflammation involving a Th2-cytokine,interleukin (IL)-13. A substantial body of evidence has accumulated pointing to the pivotal role of IL-13 in the pathogenesis of asthma, based on mainly analyses of mouse models. In addition to such analyses,the high expression of IL-13 in lesions and genetic association of several genes coding IL-13 signaling molecules with asthma have raised the possibility that IL-13 plays a pivotal role in the onset or exacerbation of human asthma. Therefore, IL-13 and its signal pathway are thought to be promising targets to develop a therapeutic agent for asthma. This article describes how IL-13 is involved in the pathogenesis of asthma and then how therapeutic agents to block IL-13 signals are developed for asthma.